Olema Pharmaceuticals (OLMA)
(Delayed Data from NSDQ)
$11.85 USD
-0.89 (-6.99%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $11.86 +0.01 (0.08%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
OLMA 11.85 -0.89(-6.99%)
Will OLMA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for OLMA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OLMA
Recent Price Trend in Olema Pharmaceuticals (OLMA) is Your Friend, Here's Why
Olema Pharmaceuticals (OLMA) Skyrockets 471% YTD: Here's Why
OLMA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Olema Pharmaceuticals, Inc. (OLMA) Is a Great Choice for 'Trend' Investors, Here's Why
Wall Street Analysts Believe Olema Pharmaceuticals, Inc. (OLMA) Could Rally 76.47%: Here's is How to Trade
Here's Why Momentum in Olema Pharmaceuticals, Inc. (OLMA) Should Keep going
Other News for OLMA
Commit To Buy Olema Pharmaceuticals At $10, Earn 48.8% Annualized Using Options
Olema Oncology price target lowered by $2 at JPMorgan, here's why
Buy Rating Reaffirmed for Olema Pharmaceuticals Amid Promising Breast Cancer Treatment Advances and Strong Financials
Oppenheimer Reaffirms Their Buy Rating on Olema Pharmaceuticals (OLMA)
Buy Rating for Olema Pharmaceuticals Based on Promising Clinical Data and Strategic Drug Positioning